27 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
15 Mar 24
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study
3:18pm
failure, acute kidney injury, disseminated intravascular coagulation and hemorrhage, HLH/MAS, angina pectoris, supraventricular and ventricular
6-K
EX-99.1
LEGN
Legend Biotech Corp
23 Feb 24
Current report (foreign)
7:16am
injury, disseminated intravascular coagulation and hemorrhage, HLH/MAS, angina pectoris, supraventricular and ventricular tachycardia, malaise, myalgias
6-K
EX-99.1
LEGN
Legend Biotech Corp
11 Dec 23
Legend Biotech Corporation 6-K
7:32pm
failure, acute kidney injury, disseminated intravascular coagulation, HLH/MAS, angina pectoris, supraventricular and ventricular tachycardia, malaise
6-K
EX-99.1
LEGN
Legend Biotech Corp
6 Jun 23
Legend Biotech Corporation 6-K
4:44pm
, hyperbilirubinemia, hypotension, pyrexia, hypoxia, respiratory failure, acute kidney injury, disseminated intravascular coagulation and hemorrhage, HLH/MAS
6-K
EX-99.1
v4noxtl3dx9uu3igv
5 Jun 23
Legend Biotech 6-K
11:17am
6-K
EX-99.1
u6kegd6pdtivd5pp7
25 May 23
Legend Biotech Corporation 6-K
8:30am
6-K
EX-99.1
rx6 9a2a3toyi74
16 May 23
Legend Biotech Corporation 6-K
8:39am
6-K
EX-99.1
kes vxf77f8
14 Apr 23
Master Technology Transfer, Manufacturing and Clinical Supply Services Agreement for Bcma Car-t Product
8:30am
6-K
EX-99.1
jx5quv j3w6pkxl
3 Nov 22
Legend Biotech Corporation 6-K
4:09pm
6-K
EX-99.1
5im9u q0mi24k660foy
27 Sep 22
Legend Biotech Corp. 6-K
9:17am
424B5
8i68m8
27 Jul 22
Prospectus supplement for primary offering
4:32pm
424B5
3zoh4wm4so4or9401
25 Jul 22
Prospectus supplement for primary offering
4:29pm
6-K
EX-99.4
t6h98atz
25 Jul 22
Legend Biotech Corporation Announces Proposed Public Offering
4:07pm
6-K
EX-99.1
tig zgq2be062
6 Jun 22
Legend Biotech Corporation Form 6-K
6:00am
6-K
EX-99.1
z7v0b8i
18 May 22
Legend Biotech Corp. 6-K
8:30am
6-K
EX-99.1
pqz2ziz5ejpt k9cisfx
1 Mar 22
Legend Biotech Corp. 6-K
6:00am
20-F
s4i m2u7z
2 Apr 21
Annual report (foreign)
8:10am